Outcome of COVID–19 among Hepatocellular Carcinoma Patients at Tertiary Care Hospital

Abstract

Objective: To determine the outcome of COVID–19 among hepatocellular carcinoma patients at tertiary care hospital.

Study Design: descriptive case series study

Place and Duration of Study: This study was conducted at the Department of Medicine, Nishtar Hospital Multan from December, 2020 to December, 2021.

Materials and Methods: All patients of hepatocellular carcinoma diagnosed with COVID–19 of either sex aged more than 20 years were included in this study. Collected Data was entered into SPSS version 22 and was analyzed through its statistical package.

Results: A total of 62 patients with hepatocellular carcinoma presenting with COVID–19 were included, of which 69.4% (n = 43) were male while 30.6 % (n = 19) were female patients. Mean age of these patients was 59.60 ± 8.94 years (range; 42–78 years). Mean duration of hospitalization in these patients was 11.37 ± 6.18 days and 58.1 % (n = 36) were hospitalized for more than 1 week. Admission to intensive care unit (ICU) was noted in 25.8% (n = 16) of these patients. In–hospital mortality in HCC patients having COVID–19 was noted in 27.4 % (n = 17).

Conclusion: High frequency of in–hospital mortality was noted in hepatocellular carcinoma patients infected with COVID–19 in our study.